Literature DB >> 8498601

Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin.

D A Scheuer1, M H Perrone.   

Abstract

Angiotensin (ANG) can produce a biphasic arterial pressure response, i.e., an increase followed by a decrease. Because ANG type 1 (AT1) receptors mediate the pressor response to ANG, we hypothesized that the opposing depressor action is mediated by the ANG type 2 (AT2) receptors. In thiobutabarbital (Inactin)-anesthetized rats bolus injections of angiotensin III (ANG III; 100, 300, and 1,000 ng/kg iv) produced peak increases in MAP at 20 s of 13.4 +/- 1.4, 20.1 +/- 2, and 27.5 +/- 2.8 mmHg and maximum decreases in pressure at 120 s of -6.3 +/- 1.5, -6.8 +/- 2.2, and -11.4 +/- 4.9 mmHg. During blockade of the AT1 receptors with DuP 753 (losartan, 10 mg/kg) the increases in MAP were eliminated (P < 0.01), whereas the depressor responses (-24.7 +/- 8, -32.8 +/- 9.3, and -42.0 +/- 10.0 mmHg) were significantly (P < 0.05) larger. In separate groups of rats, combined blockade of both AT1 and AT2 receptors eliminated all changes in MAP in response to ANG III, whereas blockade of AT2 receptors alone enhanced the pressor response to ANG III. During AT1 receptor blockade angiotensin II also caused consistent decreases in pressure, which were inhibited during combined blockade of AT1 and AT2 receptors. Therefore, we have demonstrated that the AT2 receptors mediate a depressor response to ANG.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498601     DOI: 10.1152/ajpregu.1993.264.5.R917

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

1.  The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice.

Authors:  C D Searles; D G Harrison
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  The acute vascular effects of frusemide in heart failure.

Authors:  P S Jhund; J J McMurray; A P Davie
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 3.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 4.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

Review 5.  Update on angiotensin AT2 receptors.

Authors:  Robert M Carey
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

Review 6.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

7.  Angiotensin II stimulates both aldosterone secretion and DNA synthesis via type 1 but not type 2 receptors in bovine adrenocortical cells.

Authors:  A Tanabe; M Naruse; K Arai; K Naruse; T Yoshimoto; T Seki; T Imaki; M Kobayashi; H Miyazaki; H Demura
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

8.  The role of bradykinin, AT2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat.

Authors:  R Soares de Moura; A C Resende; A F Emiliano; T Tano; A C Mendes-Ribeiro; M L G Correia; L C R Marins de Carvalho
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

9.  Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta.

Authors:  Q Li; L Zhang; M Pfaffendorf; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

10.  Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor.

Authors:  I Pörsti; A T Bara; R Busse; M Hecker
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.